CD274 and rectal cancer: By investigating three established PD-L1 scores in this retrospective analysis, we found a statistically significant survival benefit for rectal cancer patients with a higher PD-L1 TPS (>1%) compared to patients with a PD-L1 TPS ≤1% prior to neoadjuvant CRT (Figure 3A).